美国FDA批准三联疗法Trijardy™XR治疗2型糖尿病

2020-01-29 Allan MedSci原创

Trijardy™XR（依帕格列净/利格列汀/盐酸二甲双胍缓释片）是一种每日一次的三合一疗法。2020年1月27日，美国FDA批准了Trijardy™XR治疗成年人的2型糖尿病。Trijardy™XR目前由勃林格殷格翰公司和礼来公司销售。

Trijardy™XR（依帕格列净/利格列汀/盐酸二甲双胍缓释片）是一种每日一次的三合一疗法。2020年1月27日，美国FDA批准了Trijardy™XR治疗成年人的2型糖尿病。Trijardy™XR目前由勃林格殷格翰公司和礼来公司销售。

2型糖尿病是一种慢性代谢疾病，患者特征为高血糖、相对缺乏胰岛素、有胰岛素抗性等。常见症状有烦渴、频尿、不明原因的体重减轻，以上症状通常会慢慢出现。由此可见，2型糖尿病是一种复杂疾病，通常需要使用多种抗糖尿病药物来改善血糖控制。在单一片剂中使用三种不同的糖尿病药物是糖尿病治疗的重要进展。

原始出处：

https://www.firstwordpharma.com/node/1696487

本文系梅斯医学（MedSci）原创编译整理，转载需授权!

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言

评论区 (7)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=1839765, encodeId=14de1839e65d2, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Wed Sep 23 21:08:00 CST 2020, time=2020-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796465, encodeId=0fbc1e96465b1, content=<a href='/topic/show?id=0c371e8183e' target=_blank style='color:#2F92EE;'>#Trijardy™XR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17818, encryptionId=0c371e8183e, topicName=Trijardy™XR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0802500050, createdName=肉我只吃一口, createdTime=Tue Jul 28 01:08:00 CST 2020, time=2020-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379062, encodeId=42133e906234, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Sun Feb 09 19:35:37 CST 2020, time=2020-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551465, encodeId=48281551465ee, content=<a href='/topic/show?id=5d84e9716c0' target=_blank style='color:#2F92EE;'>#美国FDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79716, encryptionId=5d84e9716c0, topicName=美国FDA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a46914191431, createdName=10518098zz, createdTime=Fri Jan 31 05:08:00 CST 2020, time=2020-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1613724, encodeId=d7a61613e24a3, content=<a href='/topic/show?id=a59419e9059' target=_blank style='color:#2F92EE;'>#三联疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19790, encryptionId=a59419e9059, topicName=三联疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552519418574, createdName=12498636m55(暂无昵称), createdTime=Fri Jan 31 05:08:00 CST 2020, time=2020-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378673, encodeId=43ae3e8673ad, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/11/13/297abc49521542fee373596e497d37fc.jpg, createdBy=db695226500, createdName=1478fa69m73暂无昵称, createdTime=Thu Jan 30 14:14:01 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042943, encodeId=1fcd1042943c0, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Jan 29 17:08:00 CST 2020, time=2020-01-29, status=1, ipAttribution=)]
2020-09-23 柳叶一刀

#FDA批准#

35 0
[GetPortalCommentsPageByObjectIdResponse(id=1839765, encodeId=14de1839e65d2, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Wed Sep 23 21:08:00 CST 2020, time=2020-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796465, encodeId=0fbc1e96465b1, content=<a href='/topic/show?id=0c371e8183e' target=_blank style='color:#2F92EE;'>#Trijardy™XR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17818, encryptionId=0c371e8183e, topicName=Trijardy™XR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0802500050, createdName=肉我只吃一口, createdTime=Tue Jul 28 01:08:00 CST 2020, time=2020-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379062, encodeId=42133e906234, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Sun Feb 09 19:35:37 CST 2020, time=2020-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551465, encodeId=48281551465ee, content=<a href='/topic/show?id=5d84e9716c0' target=_blank style='color:#2F92EE;'>#美国FDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79716, encryptionId=5d84e9716c0, topicName=美国FDA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a46914191431, createdName=10518098zz, createdTime=Fri Jan 31 05:08:00 CST 2020, time=2020-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1613724, encodeId=d7a61613e24a3, content=<a href='/topic/show?id=a59419e9059' target=_blank style='color:#2F92EE;'>#三联疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19790, encryptionId=a59419e9059, topicName=三联疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552519418574, createdName=12498636m55(暂无昵称), createdTime=Fri Jan 31 05:08:00 CST 2020, time=2020-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378673, encodeId=43ae3e8673ad, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/11/13/297abc49521542fee373596e497d37fc.jpg, createdBy=db695226500, createdName=1478fa69m73暂无昵称, createdTime=Thu Jan 30 14:14:01 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042943, encodeId=1fcd1042943c0, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Jan 29 17:08:00 CST 2020, time=2020-01-29, status=1, ipAttribution=)]
2020-07-28 肉我只吃一口

#Trijardy™XR#

35 0
[GetPortalCommentsPageByObjectIdResponse(id=1839765, encodeId=14de1839e65d2, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Wed Sep 23 21:08:00 CST 2020, time=2020-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796465, encodeId=0fbc1e96465b1, content=<a href='/topic/show?id=0c371e8183e' target=_blank style='color:#2F92EE;'>#Trijardy™XR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17818, encryptionId=0c371e8183e, topicName=Trijardy™XR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0802500050, createdName=肉我只吃一口, createdTime=Tue Jul 28 01:08:00 CST 2020, time=2020-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379062, encodeId=42133e906234, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Sun Feb 09 19:35:37 CST 2020, time=2020-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551465, encodeId=48281551465ee, content=<a href='/topic/show?id=5d84e9716c0' target=_blank style='color:#2F92EE;'>#美国FDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79716, encryptionId=5d84e9716c0, topicName=美国FDA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a46914191431, createdName=10518098zz, createdTime=Fri Jan 31 05:08:00 CST 2020, time=2020-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1613724, encodeId=d7a61613e24a3, content=<a href='/topic/show?id=a59419e9059' target=_blank style='color:#2F92EE;'>#三联疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19790, encryptionId=a59419e9059, topicName=三联疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552519418574, createdName=12498636m55(暂无昵称), createdTime=Fri Jan 31 05:08:00 CST 2020, time=2020-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378673, encodeId=43ae3e8673ad, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/11/13/297abc49521542fee373596e497d37fc.jpg, createdBy=db695226500, createdName=1478fa69m73暂无昵称, createdTime=Thu Jan 30 14:14:01 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042943, encodeId=1fcd1042943c0, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Jan 29 17:08:00 CST 2020, time=2020-01-29, status=1, ipAttribution=)]
2020-02-09 wxl882001

了解一下

80 0
[GetPortalCommentsPageByObjectIdResponse(id=1839765, encodeId=14de1839e65d2, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Wed Sep 23 21:08:00 CST 2020, time=2020-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796465, encodeId=0fbc1e96465b1, content=<a href='/topic/show?id=0c371e8183e' target=_blank style='color:#2F92EE;'>#Trijardy™XR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17818, encryptionId=0c371e8183e, topicName=Trijardy™XR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0802500050, createdName=肉我只吃一口, createdTime=Tue Jul 28 01:08:00 CST 2020, time=2020-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379062, encodeId=42133e906234, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Sun Feb 09 19:35:37 CST 2020, time=2020-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551465, encodeId=48281551465ee, content=<a href='/topic/show?id=5d84e9716c0' target=_blank style='color:#2F92EE;'>#美国FDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79716, encryptionId=5d84e9716c0, topicName=美国FDA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a46914191431, createdName=10518098zz, createdTime=Fri Jan 31 05:08:00 CST 2020, time=2020-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1613724, encodeId=d7a61613e24a3, content=<a href='/topic/show?id=a59419e9059' target=_blank style='color:#2F92EE;'>#三联疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19790, encryptionId=a59419e9059, topicName=三联疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552519418574, createdName=12498636m55(暂无昵称), createdTime=Fri Jan 31 05:08:00 CST 2020, time=2020-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378673, encodeId=43ae3e8673ad, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/11/13/297abc49521542fee373596e497d37fc.jpg, createdBy=db695226500, createdName=1478fa69m73暂无昵称, createdTime=Thu Jan 30 14:14:01 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042943, encodeId=1fcd1042943c0, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Jan 29 17:08:00 CST 2020, time=2020-01-29, status=1, ipAttribution=)]
2020-01-31 10518098zz

#美国FDA#

39 0
[GetPortalCommentsPageByObjectIdResponse(id=1839765, encodeId=14de1839e65d2, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Wed Sep 23 21:08:00 CST 2020, time=2020-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796465, encodeId=0fbc1e96465b1, content=<a href='/topic/show?id=0c371e8183e' target=_blank style='color:#2F92EE;'>#Trijardy™XR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17818, encryptionId=0c371e8183e, topicName=Trijardy™XR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0802500050, createdName=肉我只吃一口, createdTime=Tue Jul 28 01:08:00 CST 2020, time=2020-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379062, encodeId=42133e906234, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Sun Feb 09 19:35:37 CST 2020, time=2020-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551465, encodeId=48281551465ee, content=<a href='/topic/show?id=5d84e9716c0' target=_blank style='color:#2F92EE;'>#美国FDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79716, encryptionId=5d84e9716c0, topicName=美国FDA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a46914191431, createdName=10518098zz, createdTime=Fri Jan 31 05:08:00 CST 2020, time=2020-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1613724, encodeId=d7a61613e24a3, content=<a href='/topic/show?id=a59419e9059' target=_blank style='color:#2F92EE;'>#三联疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19790, encryptionId=a59419e9059, topicName=三联疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552519418574, createdName=12498636m55(暂无昵称), createdTime=Fri Jan 31 05:08:00 CST 2020, time=2020-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378673, encodeId=43ae3e8673ad, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/11/13/297abc49521542fee373596e497d37fc.jpg, createdBy=db695226500, createdName=1478fa69m73暂无昵称, createdTime=Thu Jan 30 14:14:01 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042943, encodeId=1fcd1042943c0, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Jan 29 17:08:00 CST 2020, time=2020-01-29, status=1, ipAttribution=)]
2020-01-31 12498636m55(暂无昵称)

#三联疗法#

30 0
[GetPortalCommentsPageByObjectIdResponse(id=1839765, encodeId=14de1839e65d2, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Wed Sep 23 21:08:00 CST 2020, time=2020-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796465, encodeId=0fbc1e96465b1, content=<a href='/topic/show?id=0c371e8183e' target=_blank style='color:#2F92EE;'>#Trijardy™XR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17818, encryptionId=0c371e8183e, topicName=Trijardy™XR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0802500050, createdName=肉我只吃一口, createdTime=Tue Jul 28 01:08:00 CST 2020, time=2020-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379062, encodeId=42133e906234, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Sun Feb 09 19:35:37 CST 2020, time=2020-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551465, encodeId=48281551465ee, content=<a href='/topic/show?id=5d84e9716c0' target=_blank style='color:#2F92EE;'>#美国FDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79716, encryptionId=5d84e9716c0, topicName=美国FDA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a46914191431, createdName=10518098zz, createdTime=Fri Jan 31 05:08:00 CST 2020, time=2020-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1613724, encodeId=d7a61613e24a3, content=<a href='/topic/show?id=a59419e9059' target=_blank style='color:#2F92EE;'>#三联疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19790, encryptionId=a59419e9059, topicName=三联疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552519418574, createdName=12498636m55(暂无昵称), createdTime=Fri Jan 31 05:08:00 CST 2020, time=2020-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378673, encodeId=43ae3e8673ad, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/11/13/297abc49521542fee373596e497d37fc.jpg, createdBy=db695226500, createdName=1478fa69m73暂无昵称, createdTime=Thu Jan 30 14:14:01 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042943, encodeId=1fcd1042943c0, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Jan 29 17:08:00 CST 2020, time=2020-01-29, status=1, ipAttribution=)]
2020-01-30 1478fa69m73暂无昵称

学习了

87 0
[GetPortalCommentsPageByObjectIdResponse(id=1839765, encodeId=14de1839e65d2, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Wed Sep 23 21:08:00 CST 2020, time=2020-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796465, encodeId=0fbc1e96465b1, content=<a href='/topic/show?id=0c371e8183e' target=_blank style='color:#2F92EE;'>#Trijardy™XR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17818, encryptionId=0c371e8183e, topicName=Trijardy™XR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0802500050, createdName=肉我只吃一口, createdTime=Tue Jul 28 01:08:00 CST 2020, time=2020-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379062, encodeId=42133e906234, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Sun Feb 09 19:35:37 CST 2020, time=2020-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551465, encodeId=48281551465ee, content=<a href='/topic/show?id=5d84e9716c0' target=_blank style='color:#2F92EE;'>#美国FDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79716, encryptionId=5d84e9716c0, topicName=美国FDA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a46914191431, createdName=10518098zz, createdTime=Fri Jan 31 05:08:00 CST 2020, time=2020-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1613724, encodeId=d7a61613e24a3, content=<a href='/topic/show?id=a59419e9059' target=_blank style='color:#2F92EE;'>#三联疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19790, encryptionId=a59419e9059, topicName=三联疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552519418574, createdName=12498636m55(暂无昵称), createdTime=Fri Jan 31 05:08:00 CST 2020, time=2020-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378673, encodeId=43ae3e8673ad, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/11/13/297abc49521542fee373596e497d37fc.jpg, createdBy=db695226500, createdName=1478fa69m73暂无昵称, createdTime=Thu Jan 30 14:14:01 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042943, encodeId=1fcd1042943c0, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Jan 29 17:08:00 CST 2020, time=2020-01-29, status=1, ipAttribution=)]
2020-01-29 misszhang

谢谢MedSci提供最新的资讯

57 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

内分泌科

美国FDA批准三联疗法Trijardy™XR治疗2型糖尿病

相关资讯

科室

工具

服务